OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Position Increased by Peapod Lane Capital LLC

Peapod Lane Capital LLC raised its position in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 19.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 571,110 shares of the medical instruments supplier's stock after purchasing an additional 91,787 shares during the quarter. OraSure Technologies accounts for approximately 2.2% of Peapod Lane Capital LLC's portfolio, making the stock its 19th largest holding. Peapod Lane Capital LLC owned about 0.74% of OraSure Technologies worth $1,925,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of OSUR. Spire Wealth Management purchased a new stake in shares of OraSure Technologies during the 1st quarter valued at about $54,000. Assenagon Asset Management S.A. raised its holdings in shares of OraSure Technologies by 9.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 164,260 shares of the medical instruments supplier's stock valued at $554,000 after buying an additional 14,132 shares during the period. Northern Trust Corp raised its holdings in shares of OraSure Technologies by 6.7% during the 4th quarter. Northern Trust Corp now owns 693,887 shares of the medical instruments supplier's stock valued at $2,505,000 after buying an additional 43,628 shares during the period. Two Sigma Investments LP purchased a new stake in shares of OraSure Technologies during the 4th quarter valued at about $552,000. Finally, Deutsche Bank AG raised its holdings in shares of OraSure Technologies by 68.5% during the 4th quarter. Deutsche Bank AG now owns 72,672 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 29,545 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OSUR has been the topic of several analyst reports. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. Evercore ISI reiterated an "in-line" rating and set a $3.00 target price on shares of OraSure Technologies in a report on Monday, May 19th.

OraSure Technologies Trading Up 1.6%

OSUR stock traded up $0.05 during midday trading on Friday, hitting $3.10. 682,037 shares of the company's stock were exchanged, compared to its average volume of 746,030. OraSure Technologies, Inc. has a 12-month low of $2.36 and a 12-month high of $4.92. The firm has a 50 day moving average price of $2.84 and a 200-day moving average price of $3.27. The stock has a market capitalization of $231.88 million, a price-to-earnings ratio of -7.38 and a beta of 0.45.

OraSure Technologies declared that its Board of Directors has approved a stock repurchase program on Monday, March 24th that permits the company to repurchase $40.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 15.6% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its shares are undervalued.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.